Stribild (Elvitegravir/Cobicistat/FTC/Tenofovir): Research
- Updated Results on Quad: 96-Week Data From Phase 3 Studies (November/December 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
 Top 10 HIV Clinical Developments of 2012 (December 2012)
In HIV JournalView, from TheBodyPRO.com
 Dolutegravir and the 88 Percent Rule (October 28, 2012)
From Journal Watch
On TheBodyPRO.com
- Study Summaries From ICAAC 2012 (September/October 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
 Stribild (a.k.a. "Quad") Performs Well for People Over 50, Study Finds (September 23, 2012)
In The 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012), from TheBodyPRO.com
- Stribild (a.k.a. "Quad") May Slightly Outperform Other Popular First-Line Options, Study Finds (September 15, 2012)
In The 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012), from TheBodyPRO.com
- Integrated Analysis Shows "Quad" Pill Has Potent Activity With Fewer Side Effects (September 12, 2012)
From aidsmap.com
- Stribild "Quad" Pill Has Potent Anti-HIV Activity With Fewer Side Effects (September 11, 2012)
From HIVandHepatitis.com
- Studies Find Once-Daily "Quad" Is Safe and Effective (September/October 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
On TheBodyPRO.com
- Quad Matches Atripla and Atazanavir Regardless of Viral Load or CD4 Count (August 17, 2012)
From HIVandHepatitis.com
- Gilead HIV Drug as Good as Merck's Isentress: Study (August 2, 2012)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
On TheBodyPRO.com
- AIDS 2012: New Drugs and Formulations (August 1, 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Quad -- Safety and Effectiveness Issues in Depth (July 2012)
To read PDF, click here.
In Treatment Update, from Canadian AIDS Treatment Information Exchange
On TheBodyPRO.com
 Four-in-One AIDS Drug Gets the OK in Clinical Trial (June 29, 2012)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Studies on Pipeline Antiretrovirals Reveal New Data on Possible Drug Interactions (May/June 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Quad Fixed-Dose Integrase Combination: Phase 3 Studies at Week 48 (March/April 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- CROI 2012: New Full-Regimen Quad Pill as Effective as Atripla (March 26, 2012)
From Project Inform
On TheBodyPRO.com
- CROI 2012 Really Rapid Review -- With CROI 2013 Dates! (March 15, 2012)
From Journal Watch
- Gilead Quad HIV Drug Causes Fewer Side Effects (March 9, 2012)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
On TheBodyPRO.com
- Data Show Gilead's Quad Regimen for HIV Non-Inferior to Protease-Based Regimen at 48 Weeks in Second Pivotal Phase 3 Study (March 8, 2012)
From Gilead Sciences, Inc.
On TheBodyPRO.com
- Gilead's Quad Single Tablet Regimen for HIV Non-Inferior to Atripla in Pivotal Phase 3 Study (March 7, 2012)
Quad currently under review for marketing approval by U.S. and European regulatory agencies.
From Gilead Sciences, Inc.
On TheBodyPRO.com
|
Advertisement
|
Email
Glossary
